The following adverse events have been reported from clinical trial and post-marketed experience.
Frequencies are defined as: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1,000, <1/100), rare (≥1/10,000, <1/1000) and very rare (<1/10,000). (See Table 3.)
Click on icon to see table/diagram/image
Pneumonia and TSH elevations have also been reported from worldwide marketing experience with rabeprazole sodium.
View ADR Monitoring Form